Skip to main content
Year archive

MAYNE PHARMA GROUP LIMITED — 2018 filings

All 59 regulatory filings released by MAYNE PHARMA GROUP LIMITED (MYX) in 2018, sourced directly from the official regulator.

59 Filings
2018 Period
2018 filings (59)
Filing Released Lang
Change of Director's Interest Notice 2 pages 323.4KB
Director's Dealing
2018-12-30 English
Employee option exercise 1 page 257.0KB
Transaction in Own Shares
2018-12-27 English
Change of Director's Interest Notice 2 pages 350.7KB
Director's Dealing
2018-12-23 English
MYX extends debt facility and adds receivables facility 1
Capital/Financing Update
2018-12-19 English
MYX announces US commercial rights for SUBA-itra in BCCNS 3 pages 417.5KB
Capital/Financing Update
2018-12-17 English
Ceasing to be a substantial holder 2 pages 20.5KB
Major Shareholding Notification
2018-12-13 English
FDA approval of Tolsura (SUBA-itraconazole) capsules 2 pages 411.1KB
Capital/Financing Update
2018-12-11 English
Change of Director's Interest Notice 2 pages 765.4KB
Director's Dealing
2018-12-09 English
Appendix 3B 9 pages 396.4KB
Share Issue/Capital Change
2018-12-06 English
Becoming a substantial holder 4 pages 170.8KB
Regulatory Filings
2018-12-05 English
2018 AGM Chairman's Address 5 pages 259.7KB
AGM Information
2018-11-28 English
2018 AGM CEO's Speech 6 pages 258.3KB
AGM Information
2018-11-28 English
Results of 2018 AGM 2 pages 394.7KB
Declaration of Voting Results & Voting Rights Announcements
2018-11-28 English
Final Director's Interest Notice 2 pages 727.9KB
Director's Dealing
2018-11-28 English
Appendix 3B 9 pages 685.4KB
Capital/Financing Update
2018-10-30 English
Notice of Annual General Meeting / Proxy Form 12 pages 2.8MB
AGM Information
2018-10-28 English
Retirement of Director 1 page 249.3KB
Board/Management Information
2018-10-28 English
MYX announces acquisition of FDA approved halobetasol foam 3 pages 429.6KB
Capital/Financing Update
2018-10-25 English
Investor Presentation Acquisition of halobetasol foam 5 pages 657.6KB
Capital/Financing Update
2018-10-25 English
Appendix 4G and 2018 Corporate Governance Statement 27 pages 1.3MB
Governance Information
2018-10-18 English
2018 Annual Report 96 pages 5.4MB
Annual Report
2018-10-11 English
Appendix 3B, employee option exercise and option lapse 10 pages 1.1MB
Share Issue/Capital Change
2018-10-09 English
Change in substantial holding 7 pages 261.0KB
Regulatory Filings
2018-10-08 English
Appendix 3B, employee option exercise and option lapse 10 pages 822.3KB
Share Issue/Capital Change
2018-09-10 English
Change in substantial holding 9 pages 363.8KB
Major Shareholding Notification
2018-08-30 English
Full Year Statutory Accounts 73 pages 7.4MB
Annual Report
2018-08-23 English
2018 Full Year Results Media Release 6 pages 444.4KB
Annual Report
2018-08-23 English
2018 Full Year Results Investor Presentation 30 pages 1.4MB
Investor Presentation
2018-08-23 English
Appendix 3B 9 pages 690.6KB
Share Issue/Capital Change
2018-07-26 English
Mayne Pharma acquires generic Efudex in the US 2 pages 270.7KB
Capital/Financing Update
2018-07-22 English
Lapse of employee options and option exercise 1 pag
Transaction in Own Shares
2018-07-15 English
Mayne Pharma further strengthens Board with new Director 2 pages 252.9KB
Board/Management Information
2018-06-27 English
Initial Director's Interest Notice 2 pages 514.0KB
Director's Dealing
2018-06-27 English
Appendix 3B 9 pages 688.2KB
Capital/Financing Update
2018-06-19 English
Appendix 3B 9 pages 1.1MB
Share Issue/Capital Change
2018-06-14 English
Ceasing to be a substantial holder 4 pages 47.1KB
Major Shareholding Notification
2018-06-06 English
Appendix 3B 9 pages 1.0MB
Share Issue/Capital Change
2018-06-05 English
Revised Securities Trading Policy 7 pages 450.2KB
Governance Information
2018-05-30 English
Mayne Pharma strengthens Board with new Director 2 pages 257.5KB
Board/Management Information
2018-05-29 English
Initial Director's Interest Notice 2 pages 521.1KB
Director's Dealing
2018-05-29 English
SUBA-Itraconazole NDA accepted for review by US FDA 2 pages 396.2KB
Regulatory Filings
2018-05-01 English
Appendix 3B 9 pages 689.5KB
Share Issue/Capital Change
2018-04-30 English
Mayne Pharma opens new US manufacturing facility 2 pages 269.7KB
Regulatory Filings
2018-04-17 English
Mayne Pharma launches Amiodarone 200mg tablets in the US 1
Regulatory Filings
2018-04-16 English
Appendix 3B 9 pages 690.6KB
Share Issue/Capital Change
2018-04-09 English
Appendix 3B 9 pages 146.0KB
Capital/Financing Update
2018-04-08 English
Change in substantial holding 7 pages 253.2KB
Major Shareholding Notification
2018-03-27 English
Mayne Pharma launches generic Quartette in the US 1
Regulatory Filings
2018-03-26 English
Mayne Pharma's generic NuvaRing accepted for filing by FDA 2 pages 396.7KB
Regulatory Filings
2018-03-19 English
Appendix 3B and lapse of employee options 10 pages 1.1MB
Share Issue/Capital Change
2018-03-19 English
Mayne Pharma launches doxycycline IR capsules in the US 1
Regulatory Filings
2018-03-15 English
First generic launch of Ritalin LA 10mg capsules in the US 1
Regulatory Filings
2018-02-28 English
Becoming a substantial holder 7 pages 63.4KB
Major Shareholding Notification
2018-02-26 English
Half Yearly Report and Accounts 37 pages 1.3MB
Interim / Quarterly Report
2018-02-22 English
2018 Half Year Media Release 5 pages 439.0KB
Interim / Quarterly Report
2018-02-22 English
2018 Half Year Investor Presentation 27 pages 1.7MB
Investor Presentation
2018-02-22 English
Appendix 3B 9 pages 689.5KB
Share Issue/Capital Change
2018-02-19 English
Employee share scheme buyback final notice 5 pages 1.2MB
Transaction in Own Shares
2018-02-18 English
Appendix 3C - Employee Loan Scheme Buy Back 4 pages 263.3KB
Transaction in Own Shares
2018-02-01 English